Market closedNon-fractional
Lyra Therapeutics/LYRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lyra Therapeutics
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Ticker
LYRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Watertown, United States
Employees
109
Website
lyratherapeutics.com
LYRA Metrics
BasicAdvanced
$19M
Market cap
-
P/E ratio
-$1.22
EPS
0.02
Beta
-
Dividend rate
Price and volume
Market cap
$19M
Beta
0.02
Financial strength
Current ratio
4.777
Quick ratio
4.653
Long term debt to equity
43.038
Total debt to equity
48.849
Management effectiveness
Return on assets (TTM)
-38.10%
Return on equity (TTM)
-95.93%
Valuation
Price to revenue (TTM)
10.41
Price to book
0.24
Price to tangible book (TTM)
0.24
Price to free cash flow (TTM)
-0.239
Growth
Revenue change (TTM)
28.74%
Earnings per share change (TTM)
-26.06%
3-year earnings per share growth (CAGR)
-17.71%
What the Analysts think about LYRA
Analyst Ratings
Majority rating from 5 analysts.
LYRA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
400.00%
Net income
-$22M
48.34%
Profit margin
-4,480.00%
-70.33%
LYRA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.27
-$0.22
-$0.35
-
Expected
-$0.42
-$0.32
-$0.32
-$0.26
-$0.33
Surprise
-14.96%
-15.09%
-30.16%
33.59%
-
LYRA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyra Therapeutics stock?
Lyra Therapeutics (LYRA) has a market cap of $19M as of July 27, 2024.
What is the P/E ratio for Lyra Therapeutics stock?
The price to earnings (P/E) ratio for Lyra Therapeutics (LYRA) stock is 0 as of July 27, 2024.
Does Lyra Therapeutics stock pay dividends?
No, Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lyra Therapeutics dividend payment date?
Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyra Therapeutics?
Lyra Therapeutics (LYRA) has a beta rating of 0.02. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Lyra Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.